

# Novel Drug Delivery Systems

Fundamentals  
•  
Developmental Concepts  
•  
Biomedical Assessments

Yie W. Chien

# Novel Drug Delivery Systems

*Fundamentals • Developmental Concepts  
Biomedical Assessments*

**YIE W. CHIEN**

*College of Pharmacy  
Rutgers—The State University  
of New Jersey  
Piscataway, New Jersey*

with the assistance of

**Bernard E. Cabana**

*Food and Drug Administration  
Rockville, Maryland  
and*

**Stanley E. Mares**

*G. D. Searle & Co.  
Elburn, Illinois*

MARCEL DEKKER, INC. New York and Basel

Library of Congress Cataloging in Publication Data

Chien, Yie W. , [date]

Novel drug delivery systems.

(Drugs and the pharmaceutical sciences; v. 14)

Includes indexes.

1. Drugs--Controlled release. I. Cabana,

Bernard E. (II. Mares, Stanley E. III. Title.

IV. Series.

RS201.C64C47 1982 615'.6 82-4684

ISBN 0-8247-1831-3

COPYRIGHT © 1982 by MARCEL DEKKER, INC. ALL RIGHTS RESERVED

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, micro-filming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, Inc.

270 Madison Avenue, New York, New York 10016

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

## Preface

The idea guiding the writing of this book, as in my chapters written for Sustained and Controlled Release Drug Delivery Systems (J. R. Robinson, Dekker, 1978) and Drug Delivery Systems—Characteristics and Biomedical Applications (R. L. Juliano, Oxford, 1980), is to present a comprehensive and coherent treatment of the science of controlled, prolonged administration of therapeutic agents with a total integration of the basic concepts, fundamental principles, biomedical rationales, and potential applications.

Development of a viable drug delivery system with controlled-release characteristics requires not only a fundamental understanding of, but optimization of physicobiomedical sciences—pharmaceutics, pharmacokinetics, and pharmacodynamics. Therefore, controlled-release technology is an expansive science encompassing areas of interest germane to many physical and biomedical disciplines. There is, in fact, a body of information dealing with the basic concepts, and biomedical principles that has been generated to provide a foundation for the understanding and development of controlled-release drug delivery systems for the effective treatment of illness.

The purpose of this book is to provide a concise source of that core knowledge of controlled-release technology that can be shared by all wishing to acquire an understanding of how controlled-release technology can be utilized in the development of drug delivery systems with controlled-release characteristics, following sound pharmacokinetic and pharmacodynamic principles, for optimum bioavailability and maximum therapeutic efficacy.

This book is written for individuals of diverse backgrounds who are interested in the conceptualization, development, and/or optimization of drug delivery systems or who are involved in the laboratory testing,

clinical evaluation, or use of drug products. To provide readers with a broad spectrum of scientific information in a concise, systematic manner, the book is divided into 10 chapters, ranging from the logic of controlled-release drug administration (Chap. 1) to the physicochemical principles of controlled-release drug delivery (Chap. 9), and the regulatory considerations involved in controlled-release medication (Chap. 10). The drug delivery systems developed on the basis of controlled-release technology in recent years are analyzed according to the routes of administration—ocular (Chap. 2), vaginal (Chap. 3), uterine (Chap. 4), skin (Chap. 5), parenteral (Chap. 6), and implantation (Chap. 7) and a special chapter for veterinary medicine (Chap. 8). Each chapter itself is a systematic treatment of a body of scientific literature from diverse fields of pharmaceuticals, pharmacokinetics, and pharmacodynamics. This nonconventional approach to the new frontier of biomedical sciences will, to my belief, lead the readers into a more comprehensive and coherent understanding of the theoretical and practical aspects of controlled-release drug administration in an integrated form.

This book was begun in the last year of my employment with Searle Laboratories, G. D. Searle & Co., continued during my years with Endo Laboratories, E. I. duPont de Nemours & Co., and was completed after I joined the College of Pharmacy faculty at Rutgers—The State University of New Jersey. In all, it took more than three years to complete the task. I was very fortunate to have Dr. B. E. Cabana of The Food and Drug Administration and Dr. S. E. Mares of Searle Veterinary R&D Division to provide authoritative views and expertise in coauthoring and reviewing two important chapters of this book.

Yie W. Chien

## Contents

Preface	v
1. CONTROLLED-RELEASE DRUG ADMINISTRATION: LOGIC	1
I. Why a New Pharmaceutical Research and Development Strategy Is Indispensable	1
II. What Potential Benefits Can Be Derived from Controlled-Release Drug Delivery Systems	2
III. How to Achieve Controlled-Release Drug Administration	6
A. Zero-Order Kinetics	9
B. First-Order Kinetics	10
IV. Summary	11
References	11
2. OCULAR CONTROLLED-RELEASE DRUG ADMINISTRATION	13
I. Introduction	13
II. Physiology of the Eye	14
III. Glaucoma and Its Management	17
IV. Ocular Administration of Pilocarpine	18
V. Biopharmaceutics of Ocular Pilocarpine Administration	19
A. Precorneal Disposition of Pilocarpine	20
B. Transcorneal Permeation of Pilocarpine	22
C. Pharmacokinetics of Transcorneal Pilocarpine Permeation	24
D. Effects of Protein Binding on Intraocular Pilocarpine Bioavailability	28

VI. Controlled Ocular Pilocarpine Administration from Ocusert Systems	30
VII. Clinical Efficacy of Pilocarpine-Releasing Ocusert Systems	33
A. Comparative Pharmacological Activities	33
B. Continuous Treatment with Ocusert Systems	36
C. Comparative Tissue Distribution	39
D. Comparative Physiological Effects	39
VIII. Potential Development of Interests	41
A. Development of Epinephrine-Releasing Ocular Therapeutic Systems	41
B. Hydrophilic Contact Lenses as Ophthalmic Drug Delivery Systems	43
C. Ocular Controlled Administration of Anti-Inflammatory Steroids	44
References	48
 3. INTRAVAGINAL CONTROLLED-RELEASE DRUG ADMINISTRATION	 51
I. Historical Aspects of Development	51
II. Benefits of Intravaginal Controlled-Release Drug Administration	52
III. Physiology and Dynamics of the Vagina	54
A. Excitement Phase	56
B. Plateau Phase	56
C. Orgasmic Phase	57
D. Resolution Phase	58
IV. Biopharmaceutics of Intravaginal Controlled-Release Drug Administration	58
A. Theoretical Model of Intravaginal Controlled Drug Release	58
B. Intravaginal Pharmacokinetics	62
C. Vaginal Membrane Permeability	66
D. Cyclic Variation of Vaginal Membrane Permeability	71
E. Comparative Bioavailability of Intravaginal Contraceptive Devices	74
V. Biomedical Applications of Intravaginal Controlled-Release Drug Administration	78
A. Clinical Bioavailability of Vaginal Contraceptive Rings	78
B. Effect on Serum Hormonal Patterns	79
C. Cyclic Administration of Vaginal Contraceptive Rings	79
D. Multicycle Administration of Vaginal Contraceptive Rings	85
E. Intravaginal Controlled Administration of Progestin/Estrogen Combination	87

F. Induced Abortion by Prostaglandin-Releasing Vaginal Devices	91
References	93
4. INTRAUTERINE CONTROLLED-RELEASE DRUG ADMINISTRATION	97
I. Introduction	97
II. Historical Aspects of Development	99
III. The Uterus	100
A. Anatomy of the Uterus	100
B. Ovarian Hormones and the Control of Menstrual Cycles	103
C. Uterine Proteins	105
D. Cyclic Viscoelasticity of Cervical Mucus	106
E. Microbiology of Uterus and Cervix	106
F. Dynamics of the Uterus	106
IV. Developments of Medicated Intrauterine Devices	107
A. Logical Considerations in Medicated IUD Development	108
B. Copper-Bearing Intrauterine Devices	112
C. Hormone-Releasing Intrauterine Devices	125
D. Comparative Effects of Medicated and Nonmedicated IUDs	140
References	142
5. TRANSDERMAL CONTROLLED-RELEASE DRUG ADMINISTRATION	149
I. The Skin	149
A. Anatomy of the Skin	149
B. Biochemistry of the Skin	153
II. Fundamentals of Transdermal Permeation	154
A. Stratum Corneum as the Transdermal Permeation Barrier	155
B. Mechanistic Analysis of Transdermal Permeation	160
C. Biphasic Mathematical Model for Transdermal Permeation	167
D. Transdermal Permeation of Polar Nonelectrolytes	168
E. Transdermal Permeation of Ionogenic Drugs	170
F. Thermodynamics of Transdermal Permeation	177
G. Diffusional Resistance to Transdermal Permeation	180
H. Intercellular vs Transcellular Diffusion	182
I. Skin Penetration through Diffusion Shunts	183
J. Significance of Peripheral Blood Circulation	183



III. Factors Affecting Transdermal Permeability	185
A. Physicochemical Properties of the Penetrant Molecules	185
B. Physicochemical Properties of Drug Delivery Systems	188
C. Physiological and Pathological Conditions of the Skin	193
IV. Transdermal Continuous Drug Administration	199
A. Transdermal Permeation of Scopolamine	200
B. Controlled Release of Scopolamine from Transdermal Therapeutic Systems	203
C. Bioavailability of Scopolamine from Transdermal Therapeutic Systems	205
D. Clinical Evaluation of the Scopolamine-Releasing Transderm-V System	208
E. Recent Potential Developments of Interest	210
References	213
 6. PARENTERAL CONTROLLED-RELEASE DRUG ADMINISTRATION	 219
I. Introduction	219
II. Approaches to Parenteral Controlled-Release Drug Administration	220
A. Dissolution-Controlled Depot Formulations	221
B. Adsorption-Type Depot Preparations	223
C. Encapsulation-Type Depot Preparations	223
D. Esterification-Type Depot Preparations	224
III. Development of Parenteral Controlled-Release Formulations	224
A. Long-Acting Penicillin Preparations	224
B. Long-Acting Insulin Preparations	236
C. Long-Acting Vitamin B <sub>12</sub> Preparations	242
D. Long-Acting Adrenocorticotrophic Hormone Preparations	245
E. Long-Acting Steroid Preparations	247
F. Long-Acting Antipsychotic Preparations	258
G. Long-Acting Antimalarial Preparations	260
H. Long-Acting Antinarcotic Preparations	264
I. Long-Acting Contraceptive Preparations	277
IV. Biopharmaceutics of Parenteral Controlled-Release Administration	292
A. Effects of Physicochemical Properties	293
B. Effects of Physiological Conditions	299
C. Pharmacokinetic Basis of Parenteral Controlled-Release Drug Administration	302
References	304

7. IMPLANTABLE CONTROLLED-RELEASE DRUG DELIVERY SYSTEMS	311
I. Introduction	311
II. Historic Aspects of Development	312
III. Approaches to Subcutaneous Controlled-Release Drug Administration	314
A. Membrane Permeation-Controlled Drug Release	315
B. Matrix Diffusion-Controlled Drug Release	315
C. Matrix Erosion-Controlled Drug Release	316
D. Osmotic Pressure-Driving Drug Release	317
E. Vapor Pressure-Driving Drug Release	317
IV. Benefits of Subcutaneous Controlled-Release Drug Administration	318
V. Development of Subcutaneous Controlled-Release Drug Delivery Systems	320
A. Polymeric Capsule-Type Drug Delivery Systems	322
B. Polymeric Pellet-Type Drug Delivery Systems	356
C. Biodegradable Pellet-Type Drug Delivery Systems	375
D. Implantable Infusion Pump-Type Drug Delivery Systems	385
E. Osmotic Minipump-Type Drug Delivery Systems	398
References	407
8. CONTROLLED ADMINISTRATION OF ESTRUS-SYNCHRONIZING AGENTS IN LIVESTOCK	413
I. Physiology of Estrus	413
II. Approaches to Estrus Control and Synchronization	413
III. Development of Estrus-Synchronizing Drug Delivery Systems	417
A. Fluorogestone Acetate-Releasing Vaginal Sponges	417
B. Progesterone-Releasing Vaginal Spirals	425
C. Norgestomet-Releasing Subdermal Implants	429
D. Potential Development of Interest	450
References	461
9. FUNDAMENTALS OF CONTROLLED-RELEASE DRUG ADMINISTRATION	465
I. Introduction	465
A. Capsule-Type Drug Delivery Systems	465
B. Matrix-Type Drug Delivery Systems	465

II. Mechanistic Analyses of Controlled Release of Drugs	466
A. Capsule-Type Drug Delivery Systems	467
B. Matrix-Type Drug Delivery Systems	470
C. Sandwich-Type Drug Delivery Systems	474
III. Effects of Rate-Determining Parameters on Controlled-Release of Drugs	480
A. Polymer Solubility	480
B. Solution Solubility	488
C. Partition Coefficient	496
D. Polymer Diffusivity	513
E. Solution Diffusivity	529
F. Thickness of Polymer Diffusional Path	533
G. Thickness of Hydrodynamic Diffusion Layer	539
H. Drug Loading Dose	541
I. Surface Area	543
IV. Evaluations of Controlled Release of Drugs	545
A. In Vitro Evaluations	545
B. In Vivo Evaluations	561
C. In Vitro—in Vivo Correlations	563
References	571
 10. REGULATORY CONSIDERATIONS IN CONTROLLED-RELEASE MEDICATION	 575
I. Introduction	575
II. Regulatory Requirements	576
A. Requirements to Demonstrate Safety and Efficacy	576
B. Requirements to Demonstrate Controlled-Release Nature	578
III. Pharmacokinetic Considerations	579
A. Effect of Drug Release Rate and Biological Half-Life	580
B. Controlled-Release Formulations vs Multiple Dosing of Immediate-Release Formulations	582
C. Multiple Dose Steady-State Studies	585
IV. Development of in Vitro/in Vivo Correlations and Bioavailability Assurance	586
A. pH-Dependent Papaverine Formulations	586
B. Enteric-Coated Aminophylline Formulations	588
C. Sustained-Release Theophylline Formulations	589
D. Controlled-Release Drug Delivery Systems	593
References	597
 Author Index	 599
Subject Index	623

# 1

## Controlled-Release Drug Administration: Logic

### I. WHY A NEW PHARMACEUTICAL RESEARCH AND DEVELOPMENT STRATEGY IS INDISPENSABLE

One of the most pressing problems facing the U. S. pharmaceutical industry today is that in the past few years, only a very limited number of new drug products have been approved for marketing by the Food and Drug Administration (FDA). For instances, pharmaceutical companies in the United States spent \$1 billion in research and development (R&D) in 1975 alone, but produced only seven new drug entities. In strong contrast, in the middle 1950s, about 40 new drug entities were introduced yearly by the U. S. pharmaceutical companies with total annual R&D expenditure of less than \$100 million [1]. This decrease in productivity could well be related to the increasingly stringent FDA regulations that must be met before a new drug product can be introduced into the U. S. marketplace.

In order to meet the present FDA standards, the cost of testing has increased to \$10-40 million for each drug. The time span for the development of a new drug from the time when its therapeutic potential has been discovered to its market introduction has increased from an average of 2 years in the late 1950s to 10 years or more [2]. A recent report, 1978 U. S. Industrial Outlooks, by the Commerce Department pointed out that development of a new drug product runs an average net cost of \$12 million. The lack of FDA-approved drugs, the high cost of new drug development, and the expiration of patents for existing drugs means many pharmaceutical companies will be faced with a decreasing number of patent-protected drugs from which they may generate revenue.


This dilemma, faced by all pharmaceutical companies today, calls for an immediate shift in R&D emphasis. Instead of a constant search for new drugs in the traditional random, hit-or-miss way [3], new R&D strategy must focus on making clinically established drugs do their therapeutic best.

Development of novel and patentable methods of delivering these drugs, by application of the concepts and techniques of controlled-release drug administration can not only extend the patent life of the existing drugs but also minimize the scope and expenditure of testing required for FDA approval. Requirements for the approval of controlled-release formulations will be elaborated in Chap. 10 on "Regulatory Considerations in Controlled-Release Medications."

## II. WHAT POTENTIAL BENEFITS CAN BE DERIVED FROM CONTROLLED-RELEASE DRUG DELIVERY SYSTEMS

Controlled-release drug administration means not only prolonged duration of drug delivery, as in sustained release and prolonged release, but also implies predictability and reproducibility of drug release kinetics. The potential benefits that a controlled-release drug delivery system may bring to us can be appreciated by a consideration of prolonged and efficient delivery of therapeutically effective dosages, patient compliance, and localization of the therapy.

Optimal therapy of a disease requires the efficient delivery of active drugs to the tissues or organs that need treatment. Pharmacological activity and therapeutic efficacy are known to depend upon the concentration of the drug reaching the ailing tissue cells. It is usually desirable, from the standpoint of pharmacodynamics, to maintain the drug concentration in the ailing tissue cells at a constant level and within a therapeutically effective dose range for as long as the treatment requires. However, the availability of drug molecules to the cells is governed by a sequence of pharmacokinetic processes—release, absorption, distribution, and elimination (Scheme I).




(SCHEME I)

These processes could, in some cases, result in the inefficient bioavailability of the drug to the target tissue cells. Very often, doses far in excess of those required in the cells have to be administered in order to achieve the necessary therapeutically effective concentration. Unfortunately, this massive dosing frequently leads to resistance and elicits undesirable immunological and toxicological effects in nontarget tissues. The bioavailability to a target tissue can be maximized and the adverse side effects in nontarget tissue can be minimized by applying the principles of controlled drug administration.

Administration of drugs in conventional dosage forms (except via intravenous infusion at constant rate) often results in see-saw fluctuations of drug concentrations in systemic circulation (Fig. 1) and tissue compartments. The magnitude of these fluctuations depends on the rates of absorption, distribution, and elimination, and dosing intervals. The "peak and valley" pattern is more striking for drugs with a biological half-life of less than 4 hr since prescribed dosing intervals are rarely less than 4 hr. On the other hand, a drug with a long half-life has the drawback of not


FIGURE 1 Comparative serum concentration profiles of medroxyprogesterone acetate in humans resulting from continuous delivery of medroxyprogesterone acetate from the intravaginal administration of one controlled-release medicated vaginal ring (each ring contains 100 mg of medroxyprogesterone acetate) for 21 days (●) and from daily oral intake of one Provera tablet (each contains 10 mg of medroxyprogesterone acetate) for 5 consecutive days (○). [Plotted from the data by Hiroi et al., *Steroids*, 26:373 (1975) and by Thiery et al., *Contraception*, 13:605 (1976).]



permitting rapid termination of therapy when adverse effects or other medical reasons dictate such a need. A well-designed, controlled-release drug delivery system can significantly reduce the frequency of drug dosing and also maintain a more steady drug concentration in blood circulation and target tissue cells, for example, the controlled release of medroxyprogesterone acetate from medicated vaginal rings (Fig. 1).

It has also been recognized that many drugs have relatively steep dose-response relationships. The usual range of therapeutic plasma concentrations of commonly used drugs is relatively narrow: the ratio of the upper to lower concentration limit is usually around 2, for example, 4 to 8  $\mu\text{g/ml}$  for procainamide. The pronounced fluctuations resulting from the conventional drug administration are likely to yield periods of no therapeutic effect when the drug concentration is below minimum effective dose level (MED), and/or adverse reactions when the drug concentration exceeds the toxic dose level (Fig. 2). Drug concentrations can be maintained within a narrow

FIGURE 2 Theoretical illustration comparing blood drug concentration profiles of a long-acting controlled-release drug delivery system and immediate-release conventional dosage forms via various routes of administration.




therapeutic range by the use of controlled-release drug delivery systems which will also minimize the incidence and severity of adverse side effects [4].

The success of drug therapy is critically dependent upon the ability of the patient to comply with the regimen. Lack of patient compliance with prescribed drug dosage regimens is a common cause of failure to respond to treatment. This occurs particularly often with long-term treatment of chronic diseases. A patient's compliance is affected by a combination of several factors, including his awareness of the disease process, his faith in the therapy, his understanding of the need to adhere to a strict treatment schedule, the complexity of the therapeutic regimen, the cost of therapy, and the magnitude of local and/or systemic drug side effects. The problem of lack of patient compliance can be resolved with the use of controlled-release drug delivery systems. The prolonged release characteristics of the controlled-release drug delivery systems minimize the need for frequent drug intake (Fig. 3) and thus assures better compliance with the prescribed medication regimen. The medicated vaginal ring for cyclic contraception, for example, eliminates the need for daily oral administration of contraceptive pills (Chap. 3).

The controlled-release drug delivery systems can be designed to release drugs in the vicinity of the target tissues that require treatment while drug exposure of other, nontarget tissue is minimized. The advantages of such selectivity are exemplified by the development of intrauterine contraceptive devices which selectively release contraceptive agents such as copper (Cu-7) and natural progesterone (Progestasert) to the endometrium, the desired site of contraceptive action (Chap. 4). The localization of drug

FIGURE 3 Theoretical illustration comparing blood drug concentration profiles resulting from administration of multiple doses of a conventional dosage form ( $A_1, A_2, A_3, \dots$ ) and a single dose of a long-acting, controlled-release drug delivery system (B).





administration directly to the target tissue significantly reduces the dose and therefore minimizes the drug concentrations in tissues which do not require any medication. The occurrence of adverse side effects from a drug is thus eliminated.

The therapeutic effectiveness of a drug, i. e., the overall pharmacological response per unit dose, can be enhanced by choosing the optimal drug delivery rate, the rate that yields the most effective drug concentration in the target tissue cells. This is exemplified by the pilocarpine-releasing ocular insert (Ocuser) for the treatment of glaucoma (Chap. 2). The use of controlled-release drug delivery systems maximizes the bioavailability and, therefore, the therapeutic effectiveness of pilocarpine and minimizes the incidence of drug concentration peaks and ineffective concentration valleys.

### III. HOW TO ACHIEVE CONTROLLED-RELEASE DRUG ADMINISTRATION

The therapeutic efficacy of a drug, under clinical conditions, is not simply a function of its intrinsic pharmacologic activity. Of equal importance is the path the drug molecules must take in getting from the site of administration to the target site(s) of action. Various conditions the drug molecules encounter along the path of distribution may alter either the effectiveness of the drug or affect the amount of the drug reaching the site(s) of pharmacologic action [5].

As illustrated in the flow diagram in Fig. 4, the path followed by the drug molecules to their sites of action consists of a number of intermediate steps. Each of these steps may determine, to various degrees, the bioavailability of the drug to its target tissue and, therefore, the onset, intensity, and duration of its intrinsic pharmacologic activity. All of these intermediate steps can be grouped and classified into three main branches of the pharmaceutical sciences:

1. Pharmaceutics refers to the development/manufacturing of an efficient, economic, and palatable delivery system (dosage form), in which the drug has maximum physicochemical stability and optimum bioavailability.
2. Biopharmaceutics/pharmacokinetics refers to the study of the absorption, distribution, metabolism, and excretion of a drug before and after reaching the target site(s) of action, and the evaluation of the relationship between delivery system and therapeutic response.